Physician profile
Jay Weitzner
NPI 1649259276
$889.50
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568 · 2020: $69.11 · 2021: $130 · 2022: $122.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $228.89 | 2019-2022 | |
| Amgen INC. | $79.83 | 2019 | |
| Lilly USA, LLC | $76.39 | 2019-2022 | |
| Genzyme Corporation | $62.62 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $60.82 | 2019 | |
| Janssen Biotech, INC. | $51.48 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $40.76 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $40.52 | 2019 | |
| Sandoz INC. | $34.05 | 2019 | |
| Biofrontera INC. | $28.89 | 2022 | |
| Pfizer INC. | $27.22 | 2019 | |
| Celgene Corporation | $22.88 | 2019 | |
| Almirall LLC | $21.09 | 2019 | |
| Leo Pharma INC. | $20.27 | 2019 | |
| Aclaris Therapeutics, INC. | $19.82 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $18.46 | 2020 | |
| Incyte Corporation | $15.95 | 2022 | |
| Mission Pharmacal Company | $14.25 | 2019 | |
| Kyowa Kirin, INC. | $14.16 | 2019 | |
| Galderma Laboratories, L.P. | $11.15 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Weitzner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.